Vapotherm (NYSE: VAPO) upgraded at Zacks Investment Research

Vapotherm (NYSE: VAPO – Get a review) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a research note released Saturday to investors, reports.

According to Zacks, “Vapotherm Inc. is a medical technology company. It designs and develops respiratory devices for the treatment of chronic lung and acute respiratory disorders. The Company provides vapor transfer cartridges, delivery tubes and disinfection kits. Vapotherm Inc. is based in Exeter, New Hampshire. “

Other equity research analysts have also recently published research reports on the company. Canaccord Genuity Group lowered its target price on Vapotherm from $21.00 to $12.00 and set a “buy” rating on the stock in a Wednesday, April 13 report. Canaccord Genuity Group reduced its price target on Vapotherm from $21.00 to $12.00 in a Wednesday, April 13 research note. Piper Sandler downgraded Vapotherm from an “overweight” rating to an “underweight” rating and lowered its price target for the company from $23.00 to $8.00 in a Thursday, April 7 research report. Finally, BTIG Research lowered its price target on Vapotherm shares from $37.00 to $10.00 in a Monday, April 18 research report. One financial analyst has assigned the stock a sell rating, one has issued a hold rating and three have assigned the stock a buy rating. According to, the stock currently has an average rating of “Hold” and an average target price of $13.00.

VAPO shares opened at $5.30 on Friday. Vapotherm has a 12-month low of $5.27 and a 12-month high of $31.87. The company has a current ratio of 2.54, a quick ratio of 1.70 and a debt ratio of 0.60. The stock has a 50-day simple moving average of $12.39 and a 200-day simple moving average of $17.44. The company has a market capitalization of $138.78 million, a price-earnings ratio of -2.30 and a beta of -1.07.

Vapotherm (NYSE:VAPO – Get Rating) last released its quarterly results on Thursday, February 24. The company reported ($0.71) earnings per share (EPS) for the quarter, missing Zacks’ consensus estimate of ($0.62) by ($0.09). The company posted revenue of $22.24 million for the quarter, versus analyst estimates of $17.39 million. Vapotherm had a negative net margin of 52.78% and a negative return on equity of 68.51%. Vapotherm’s revenue was down 45.6% year over year. In the same quarter a year earlier, the company posted ($0.51) earnings per share. On average, stock analysts expect Vapotherm to post -2.5 earnings per share for the current fiscal year.

Hedge funds and other institutional investors have recently changed their stakes in the company. Dark Forest Capital Management LP purchased a new stake in Vapotherm in the third quarter for $48,000. Macquarie Group Ltd. increased its stake in Vapotherm by 211.6% during the 3rd quarter. Macquarie Group Ltd. now owns 2,315 shares of the company valued at $52,000 after purchasing an additional 1,572 shares during the period. BNP Paribas Arbitrage SA increased its position in Vapotherm by 362.2% in the third quarter. BNP Paribas Arbitrage SA now owns 4,160 shares in the company worth $93,000 after purchasing an additional 3,260 shares in the last quarter. Royal Bank of Canada increased its stake in Vapotherm shares by 40.0% in the second quarter. Royal Bank of Canada now owns 4,332 shares of the company valued at $103,000 after purchasing an additional 1,237 shares during the period. Finally, Advisor Group Holdings Inc. increased its equity stake in Vapotherm by 261.0% during the fourth quarter. Advisor Group Holdings Inc. now owns 7,968 shares of the company valued at $166,000 after purchasing an additional 5,761 shares in the last quarter. 72.20% of the shares are currently held by hedge funds and other institutional investors.

About Vapotherm (Get a rating)

Vapotherm, Inc, a medical technology company, is focused on developing and commercializing proprietary high-velocity therapy products used to treat patients of various ages with respiratory distress in the United States and around the world. The company offers precision flow systems, such as Precision Flow Hi-VNI, Precision Flow Plus, Precision Flow Classic and Precision Flow Heliox, which deliver high velocity heated, humidified and oxygenated air to patients through a nasal interface of small diameter.

Recommended Stories

Get a Free Copy of Zacks Research Report on Vapotherm (VAPO)

For more information on Zacks Investment Research’s research offerings, visit

Get news and reviews for Vapotherm Daily – Enter your email address below to receive a concise daily summary of the latest news and analyst ratings for Vapotherm and related companies with’s FREE daily newsletter.

Comments are closed.